高级搜索

雄激素阻断治疗后前列腺癌组织中肿瘤干细胞比例变化

陈 伟, 王国民

陈 伟, 王国民. 雄激素阻断治疗后前列腺癌组织中肿瘤干细胞比例变化[J]. 肿瘤防治研究, 2014, 41(02): 128-130. DOI: 10.3971/j.issn.1000-8578.2014.02.008
引用本文: 陈 伟, 王国民. 雄激素阻断治疗后前列腺癌组织中肿瘤干细胞比例变化[J]. 肿瘤防治研究, 2014, 41(02): 128-130. DOI: 10.3971/j.issn.1000-8578.2014.02.008
CHEN Wei, WANG Guomin. Androgen Deprivation Therapy Can Change Proportion of Prostate Cancer Stem Cells CHEN Wei, WANG Guomin[J]. Cancer Research on Prevention and Treatment, 2014, 41(02): 128-130. DOI: 10.3971/j.issn.1000-8578.2014.02.008
Citation: CHEN Wei, WANG Guomin. Androgen Deprivation Therapy Can Change Proportion of Prostate Cancer Stem Cells CHEN Wei, WANG Guomin[J]. Cancer Research on Prevention and Treatment, 2014, 41(02): 128-130. DOI: 10.3971/j.issn.1000-8578.2014.02.008

雄激素阻断治疗后前列腺癌组织中肿瘤干细胞比例变化

基金项目: 教育部博士点专项基金资助项目(20090071120024)
详细信息
    作者简介:

    陈伟(1978-),男,博士,主治医师,主要从事泌尿系肿瘤的基础和临床研究

    通讯作者:

    王国民,E-mail:wangguomin@zs-hospital.sh.cn

  • 中图分类号: R737.25

Androgen Deprivation Therapy Can Change Proportion of Prostate Cancer Stem Cells CHEN Wei, WANG Guomin

  • 摘要: 目的 研究雄激素阻断治疗(androgen deprivation therapy ,ADT)对前列腺癌组织中肿瘤干细胞比例的影响,探讨激素非依赖性前列腺癌形成的机制。方法 实验分为ADT治疗组和无ADT 治疗组,应用免疫荧光技术比较两组前列腺癌患者术前术后标本中肿瘤干细胞的比例变化。结果 无ADT组术前穿刺标本和前列腺根治切除术后标本肿瘤干细胞比例差异无统计学意义[(3.56±1.33)% vs. (3.78±1.39)%, n=9, t=-0.686, P=0.512] ,在ADT组,接受雄激素阻断治疗3月后,与穿刺标本比较,根治切除标本中前列腺癌肿瘤干细胞比例明显升高[(3.44±1.81)% vs. (9.22±1.71)% ,n=9, t=-6.353, P=0.000]。在癌旁组织,也可见ADT后干细胞标志的增加。结论 雄激素可能参与前列腺和前列腺癌组织中干细胞的分化;雄激素非依赖性前列腺癌的形成可能与前列腺癌肿瘤干细胞有关。

     

    Abstract: Objective To study the effect of androgen deprivation therapy on prostate cancer stem cells in prostate cancer tissues and to investigate the mechanisms of the formation of androgen independent prostate cancer. Methods Eighteen patients were divided into 2 groups, the ADT (androgen deprivation therapy) group and non-ADT group. The proportions of cancer stem cells in preoperative and postoperative prostate cancer tissues were compared with immunofl uorescence. Results In the non-ADT group, the differences of cancer stem cell proportion between preoperative and postoperative specimens were not prominent[(3.56±1.33)% vs. (3.78±1.39)%, n = 9, t =-0.686, P = 0.512]. But in the ADT group, compared with preoperative specimens, the proportion of prostate cancer stem cells was signifi cantly increased after undergoing androgen deprivation therapy for 3 months [(3.44±1.81)% vs. (9.22±1.71)%, n = 9, t = -6.353, P = 0.000]. In the tissue adjacent to carcinoma, stem cell markers were also increased after ADT. Conclusion Androgen probably is involved in the differentiation of prostate stem cells or prostate cancer stem cells. The formation of androgen independent prostate cancer may be related to prostate cancer stem cells.

     

  • [1] Labrie F, Dupont A, Cusan L, et al. Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience[J]. J Steroid Biochem,1990,37(6):943-50.
    [2] Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.[J]. J Urol,2002,168(1):9-12.
    [3] Macfarlane RJ, Chi KN. Research in castration-resistant prostate cancer: what does the future hold?[J]. Curr Oncol,2010,17 Suppl 2: S80-6.
    [4] Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group[J]. J Clin Oncol,2008,26(7):1148-59.
    [5] Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer[J]. Eur Urol,2008,53(1):68-80.
    [6] Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: the 4 R’s of radiobiology revisited[J]. Stem Cells,2010,28(4):639-48.
    [7] Silvestre DC, Pineda JR, Hoffschir F, et al. Alternative lengthening of telomeres in human glioma stem cells[J]. Stem Cells,2011,29(3):440-51.
    [8] Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer[J]. Nature, 2001,411(6835):349-54.
    [9] Rizzo S, Hersey JM, Mellor P, et al. Ovarian cancer stem celllike side populations are enriched following chemotherapyy and overexpress EZH2[J]. Mol Cancer Ther,2011,10(2):325-35.
    [10] Wei J, Barr J, Kong LY, et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway[J]. Mol Cancer Ther,2010,9(1):67-78.
    [11] Kawasaki BT, Mistree T, Hurt EM, et al. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells[J]. Biochem Biophys Res Commun,2007,364(4):778-82.
    [12] Collins AT, Berry PA, Hyde C, et al. Prospective identifi cation of tumorigenic prostate cancer stem cells[J]. Cancer Res,2005,65(23): 10 946-51.
    [13] Collins AT, Habib FK, Maitland NJ, et al. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression[J]. J Cell Sci,2001,114(Pt21): 38 65-72.
    [14] Liu AY. Differential expression of cell surface molecules in prostate cancer cells[J]. Cancer Res,2000, 60(13):3429-34 [15] Wei C,Guomin W,Yujun L,et al.Cancer stem-like cells in human prostate carcinoma cells DU145:the seeds of the cell line?[J]. Cancer Biol Ther,2007,6(5):763-8.
计量
  • 文章访问数:  1246
  • HTML全文浏览量:  317
  • PDF下载量:  602
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-08-27
  • 修回日期:  2013-10-13
  • 刊出日期:  2014-02-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭